🔗 Share this article Social Media Content Creators Driving Unofficial Market for Unlicensed Slimming Drug An underground market for unapproved weight-loss drugs is propelled by social media fitness personalities and sellers on communication apps, according to new investigations. Investigational Drug Acquiring Popularity Online The experimental drug, which remains in research studies, is being promoted by online personalities for its alleged weight-reducing properties. Viewers are encouraged to contact these profiles directly for supplier links, while also obtaining promotional offers. Thriving Trade on Messaging Platforms Additionally, a robust trade exists on Telegram, where groups with thousands of participants share “before and after” photos, administration instructions and claims of rapid British shipping. Vendors market the drug there before directing buyers to other platforms for purchases. Understanding The Experimental Drug Retatrutide is an investigational injectable developed by American pharmaceutical company Eli Lilly. The drug targets three intestinal hormones – GLP-1, GIP and pancreatic hormone. Preliminary studies indicate it could assist individuals reduce up to a quarter of their total weight. Nicknamed the “triple G”, the substance is being hailed digitally as the successor to Ozempic. Medical Experts Express Worries However, physicians and pharmacists have cautions that the distribution of what is still an unapproved drug in the UK is a cause for concern and could lead to users injecting products of uncertain source. Several experts stated the demand for retatrutide could be connected to the rising price of licensed weight loss treatments such as Mounjaro. Regulatory Position and Enforcement Selling the unapproved drug on social media or messaging apps is prohibited in the UK, as it is an unlicensed drug that cannot be promoted or supplied for human use under the Human Medicines Regulations 2012. Several content creators attempt to sidestep the rules by referring to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled drug, but promotion and supply can still violate medicines, marketing, and consumer regulations, potentially leading to penalties, prosecution or imprisonment. Platform Reaction and Content Removal Based on TikTok, the platform has removed violative material and banned associated hashtags and search suggestions. The organization stated it was committed to maintaining the service safe and allocating resources in enhancing compliance measures. Digital Marketplace Operations Research also found communities with up to nine thousand members marketing retatrutide using Telegram's built-in search feature, which operates like a online catalog. Typing “retatrutide” instantly brings up groups with thousands of members, filled with images of slimming results, glowing reviews and detailed guides for mixing or administering at home. After minutes of entering one community, a seller shared contact information, where most transactions occur. The vendor provided an guidebook and promised delivery within two days. When asked whether the substance was authentic, one seller responded: “You can’t be sure.” Another provided a photo of a alleged laboratory certificate. None inquired about body mass, medical conditions or past usage. Product Details and Costs Within these communities, posts show black plastic parcels with postal service labels, claiming to contain new batches. One message stated: “It took eight of us to load them this morning.” Customers can choose between dry substance containers, prepared at home with sterile water, or ready-to-use injectors typically sold at £160 for 20mg. When asked how long a pen should last, vendors give conflicting answers ranging from a several days to “depends on your body”. Platform Moderation and Security Measures A spokesperson for the messaging service said it actively monitored dangerous material on its service including content that encouraged the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”. Healthcare Expert Warnings “Individuals are injecting substances they cannot confirm. Even if the science behind retatrutide is valid, these digital versions may not include what they advertise,” stated a pharmacy expert, the director of pharmacy at a pharmacy service. Dr Crystal Wyllie of Asda Online Doctor linked the surge in interest to current price rises for authorized slimming medications such as Mounjaro. “With costs rising, patients are turning to social media. But counterfeit treatments are extremely dangerous. You cannot know what’s contained or whether the environment they were made in was sterile,” she said. Her team has already seen patients injured by personal administration from unverified sources. “We understand the frustration, but buying from Telegram or WhatsApp is gambling with your well-being,” said the doctor. “These materials could be impure or improperly measured.” Producer Statement A representative from Eli Lilly stated retatrutide was in phase 3 clinical trials and had not been evaluated or approved by any regulatory agency globally. “Therefore at this time no one can sell [it] for personal consumption,” they explained, adding that any product “falsely representing itself as a company investigational product not yet approved … may expose patients to potentially significant medical dangers”.